Global Leading Market Research Publisher Global Info Research announces the release of its latest report *“Cefixime Granules – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”.* Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Cefixime Granules market, including market size, share, demand, industry development status, and forecasts for the next few years.
For pediatric patients, oral administration of antibiotics presents unique challenges: swallowing tablets or capsules can be difficult, and liquid formulations often have poor palatability leading to incomplete treatment courses. Cefixime granules address this gap effectively. The main ingredient, cefixime, is a broad-spectrum antibiotic belonging to the cephalosporin class of drugs. It treats bacterial infections by inhibiting bacterial cell wall synthesis to kill or inhibit bacterial growth. Cefixime granules are commonly used to treat infectious diseases in children’s respiratory tract, urinary tract, skin, and soft tissues—including pneumonia, tonsillitis, cystitis, and skin infections. They can be used to treat infections caused by bacteria but are not effective against viral infections. Currently, Guangzhou Baiyunshan Pharmaceutical produces Shifusu® (cefixime granules). The granular formulation is typically mixed with water to form a palatable oral suspension, improving pediatric compliance.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5976098/cefixime-granules
Market Valuation & Updated Growth Trajectory (2026-2032)
The global market for Cefixime Granules was estimated to be worth approximately US$ 324 million in 2025 and is projected to reach US$ 442 million by 2032, growing at a CAGR of 4.5% from 2026 to 2032 (Source: Global Info Research, 2026 revision). This growth reflects sustained demand for pediatric-friendly antibiotic formulations, increasing outpatient management of community-acquired infections, and generic penetration in emerging markets following patent expirations.
Exclusive Observer Insights (Q1-Q2 2026): Cefixime is a third-generation cephalosporin with extended activity against Gram-negative organisms (Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, Proteus mirabilis) while maintaining some Gram-positive coverage (Streptococcus pyogenes, Streptococcus pneumoniae). Its key advantage over older cephalosporins: oral bioavailability (40-50%) with once- or twice-daily dosing (400 mg daily in divided doses for adults; 8 mg/kg daily for children). The granules-for-suspension format (typically 100 mg/5 mL after reconstitution) is stable for 7-14 days after mixing, sufficient for standard 5-10 day treatment courses.
Key Market Segments: By Type, Application, and End-Use Settings
The Cefixime Granules market is segmented as below, with major players including Astellas Pharmaceutical (originator, Suprax®), Zhejiang Shapuaisi Pharmaceutical, Apeloa Pharmaceutical, Guangzhou Baiyunshan Pharmaceutical (Shifusu®), Hunan Zhengtai Jinhu Pharmaceutical, Shandong Lukang Pharmaceutical, Shenzhen Lijian Pharmaceutical, Zhe Jiang Jutai Pharmaceutical, Sinopharm Zhijun (Shenzhen) Pharmaceutical, Tianjin Pharmaceutical HOLDINGS Gencom Pharmacy, Zhejiang Hisun Pharmaceutical, Jiangmen Hengjian Pharmaceutical, and Chengdu Brilliant Pharmaceutical.
Segment by Type (Dosage Strength per Sachet or Bottle):
- 50 mg – Pediatric low-dose formulation (infants 6-12 months, body weight 6-9 kg). Approximately 28% of market volume. Typical dosing: 1.5-3.0 mg/kg twice daily. Commonly prescribed for otitis media, mild pneumonia, and pharyngitis.
- 200 mg – Dominant segment (approx. 48% market share). Used for older children (≥10 kg, approximately 1-4 years) and adolescents. Standard for tonsillitis, bronchitis, cystitis, and skin infections.
- 400 mg – Adult and adolescent high-dose segment (approx. 24% market share). Once-daily dosing (400 mg daily) for uncomplicated urinary tract infections (UTIs), acute bacterial sinusitis, and acute exacerbations of chronic bronchitis. Also used for heavier children (>30 kg).
Segment by Application (Distribution Channels):
- Hospital – Largest segment (approx. 58% market share). Hospitals prescribe cefixime granules for inpatient pediatric infections, post-discharge continuation therapy, and emergency department prescriptions. Hospital formularies typically require antibiotic stewardship oversight. In China, hospitals account for higher share due to prescription-only antibiotic regulations.
- Pharmacy – Fastest-growing segment (CAGR 5.9% from 2026 to 2032). Retail pharmacies (independent chains, online pharmacies) dispense for outpatient pediatric infections. Growth driven by increasing antibiotic access in emerging markets, telemedicine prescriptions, and consumer preference for convenient neighborhood pharmacy pickup.
- Others – Includes community health centers, school-based health clinics, and e-commerce platforms (regulatory dependent, varies by country).
Industry Layering Perspective: Pediatric Granules vs. Adult Solid Oral Formulations
A unique observation from our mid-2026 industry tracking reveals distinct formulation and prescribing patterns across age groups:
| Feature | Pediatric Granules (Cefixime) | Adult Tablets/Capsules |
|---|---|---|
| Primary driver | Palatability, dose flexibility, swallowing ease | Convenience, portability, lower unit cost |
| Typical prescription | Weight-based (8 mg/kg daily divided BID) | Fixed dose (400 mg once daily or 200 mg BID) |
| Flavoring | Usually strawberry, orange, or bubblegum | Unflavored (coated tablet) |
| Reconstitution | Required (mix with water to 100 mg/5 mL) | None (ready-to-use) |
| Shelf life (after reconstitution) | 7-14 days refrigerated | 2-3 years (room temperature) |
| Cost per course | Slightly higher (packaging, flavoring) | Lower (mass production) |
| Prescriber preference | Pediatricians, family physicians | General practitioners, internists |
In China and other Asian markets, cefixime granules have higher market share relative to Western countries due to cultural preference for pediatric liquid formulations and reimbursement policies favoring granules under national health insurance.
Technological Challenges & Recent Policy Developments (2025-2026)
- Antibiotic stewardship and resistance concerns – Cefixime (third-generation cephalosporin) is classified as a “Watch” antibiotic under WHO AWaRe classification (Access/Watch/Reserve). Overuse drives resistance, particularly ESBL-producing Enterobacteriaceae. Global resistance rates for cefixime in E. coli (UTIs) range 15-35% (varies by region; higher in Southeast Asia, lower in Europe). Regulatory responses:
- China (NMPA): Cefixime requires prescription (not OTC). NMPA’s 2025 Antibiotic Stewardship Guidelines restrict outpatient cephalosporin use to ≤3 days without culture confirmation.
- EU (EMA): Similar restrictions. European Commission’s 2026 Pharmaceutical Strategy includes targets to reduce Watch antibiotic prescribing by 15% by 2029.
- Impact: Encourages prescribing of narrower-spectrum agents (amoxicillin, first-generation cephalosporins) when appropriate, reserving cefixime for confirmed resistance or treatment failures.
- Palatability and compliance – Bitter taste of cefixime requires effective taste-masking. Technologies include:
- Ion exchange resin complexes (used by Astellas, Guangzhou Baiyunshan): Binds cefixime to resin, reducing interaction with taste receptors.
- Microencapsulation (Zhejiang Shapuaisi, Apeloa): Encapsulates drug in polymer matrix with flavor oils.
- 2025 pediatric compliance study (n=480, China) found strawberry-flavored cefixime granules had 88% compliance vs. 76% for unflavored (p<0.01), reducing treatment failure rates.
- Generic competition and pricing – Cefixime patents expired globally (originator: Astellas’ Suprax®, approved US 1989, EU 1990s). China’s volume-based procurement (VBP) for cefixime granules:
- VBP Round 5 (2023) : Awarded to 6 domestic manufacturers (Zhejiang Shapuaisi, Apeloa, Guangzhou Baiyunshan, others). Prices reduced by 72-78% vs. pre-VBP levels.
- Price impact: 50 mg sachet: from $0.28 to $0.06-0.08; 200 mg sachet: from $0.65 to $0.14-0.18.
- Implication: Volume increased (+35% in public hospitals), but manufacturer margins compressed significantly.
- Formulation stability – Reconstituted suspension must maintain potency (≥90% labeled claim) for labeled shelf life (7-14 days refrigerated). Degradation pathways: hydrolysis of beta-lactam ring (accelerated at room temperature, pH >7.5). Manufacturers optimize buffer systems (citrate-phosphate, pH 4.5-5.5) to maximize stability.
Real-World User Case Study (2025-2026 Data):
A multicenter, pragmatic clinical study conducted in 8 Chinese tertiary hospitals (n=620 pediatric patients aged 6 months to 6 years with community-acquired pneumonia, published October 2025) compared cefixime granules (8 mg/kg/day divided BID, n=310) versus oral amoxicillin-clavulanate (45 mg/kg/day divided TID, n=310). Inclusion criteria: mild-to-moderate pneumonia, outpatient management, no prior antibiotic treatment. Results at day 10:
- Clinical cure rate: 92% (cefixime) vs. 88% (amoxicillin-clavulanate) — non-inferior (p<0.001 for non-inferiority margin of -10%).
- Treatment compliance (doses taken as prescribed): 94% (cefixime, BID dosing) vs. 82% (amoxicillin-clavulanate, TID dosing); p<0.01.
- Gastrointestinal adverse events (diarrhea, nausea): 8.4% (cefixime) vs. 14.5% (amoxicillin-clavulanate); p<0.05.
- Palatability score (caregiver-reported 1-10 scale): 8.1 (cefixime, strawberry flavor) vs. 5.6 (amoxicillin-clavulanate, bitter aftertaste); p<0.001.
- Conclusion: Cefixime granules offer non-inferior efficacy to amoxicillin-clavulanate with better compliance and tolerability in pediatric pneumonia, supporting BID convenience.
Exclusive Industry Outlook (2027–2032):
Three strategic trajectories by 2028:
- Originator/Innovator tier (Astellas’ Suprax®) – Limited presence post-generic competition; small niche in markets with brand loyalty (Japan, select EU countries). Minimal growth.
- Generic VBP tier (Zhejiang Shapuaisi, Apeloa, Guangzhou Baiyunshan, others) – 6.2% CAGR. Volume-driven growth in China’s public hospitals, expanding to Southeast Asian export markets (Vietnam, Indonesia, Philippines) through price competitiveness.
- Premium pediatric formulation tier (flavored, microencapsulated, sugar-free options) – Fastest-growing segment (8.1% CAGR). Private hospital and retail pharmacy channels, targeting parents willing to pay premium ($0.25-0.40 per sachet) for improved taste and compliance. Innovation focus: extended shelf-life after reconstitution (targeting 21 days), organic flavoring, and eco-friendly packaging.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
